Evidence map›Paper›PMID 27755544›Full record

ArticlePLoS neglected tropical diseases2016

Using C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic Activity.

Mark D Mathew, Neal D Mathew, Angela Miller, Mike Simpson, Vinci Au, Stephanie Garland, Marie Gestin, Mark L Edgley, Stephane Flibotte, Aruna Balgi and 9 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Review
  2. Article
  3. Optimizing amicroPublication biology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Essential Oils as Novel Anthelmintic Drug Candidates.Molecules (Basel, Switzerland) · 2022
    Review
  8. Article
  9. Article
  10. Frontiers in pharmacology · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Impact of drug solvents onToxicology reports · 2021
    Article
  15. Review
  16. Caenorhabditis elegans in anthelmintic research - Old model, new perspectives.International journal for parasitology. Drugs and drug resistance · 2020
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mark D MathewDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Neal D MathewDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Angela MillerDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Mike SimpsonDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Vinci AuDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Stephanie GarlandDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Marie GestinUniversite de Poitiers, Poitiers, France.
Mark L EdgleyDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Stephane FlibotteDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Aruna BalgiDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.
Jennifer ChiangDepartment of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Guri GiaeverDepartment of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Pamela DeanDepartment of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Audrey TungSummerland Research and Development Centre, Agriculture and Agri-Food Canada, Summerland, British Columbia, Canada.
Michel RobergeDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.
Calvin RoskelleyDepartment of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Tom ForgeSummerland Research and Development Centre, Agriculture and Agri-Food Canada, Summerland, British Columbia, Canada.
Corey NislowDepartment of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Donald MoermanDepartment of Zoology and Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe lack of new anthelmintic agents is of growing concern because it affects human health and our food supply, as both livestock and plants are affected. Two principal factors contribute to this problem. First, nematode resistance to anthelmintic drugs is increasing worldwide and second, many effective nematicides pose environmental hazards. In this paper we address this problem by deploying a high throughput screening platform for anthelmintic drug discovery using the nematode Caenorhabditis elegans as a surrogate for infectious nematodes. This method offers the possibility of identifying new anthelmintics in a cost-effective and timely manner. METHODS/PRINCIPAL

findingsUsing our high throughput screening platform we have identified 14 new potential anthelmintics by screening more than 26,000 compounds from the Chembridge and Maybridge chemical libraries. Using phylogenetic profiling we identified a subset of the 14 compounds as potential anthelmintics based on the relative sensitivity of C. elegans when compared to yeast and mammalian cells in culture. We showed that a subset of these compounds might employ mechanisms distinct from currently used anthelmintics by testing diverse drug resistant strains of C. elegans. One of these newly identified compounds targets mitochondrial complex II, and we used structural analysis of the target to suggest how differential binding of this compound may account for its different effects in nematodes versus mammalian cells. CONCLUSIONS/SIGNIFICANCE: The challenge of anthelmintic drug discovery is exacerbated by several factors; including, 1) the biochemical similarity between host and parasite genomes, 2) the geographic location of parasitic nematodes and 3) the rapid development of resistance. Accordingly, an approach that can screen large compound collections rapidly is required. C. elegans as a surrogate parasite offers the ability to screen compounds rapidly and, equally importantly, with specificity, thus reducing the potential toxicity of these compounds to the host and the environment. We believe this approach will help to replenish the pipeline of potential nematicides.

Indexed as

AnimalsAntinematodal AgentsCaenorhabditis elegansDrug Evaluation, PreclinicalHumansNematodaNematode InfectionsReverse GeneticsAntinematodal Agents

Identifiers

PMID27755544
PMCPMC5068747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.